Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2003

View Archived Issues

Concerta approved for ADHD in Canada

Grant supports development of cancer vaccines at Epimmune using analogue epitopes

Sustained symptom relief induced by tamsulosin in BPH

Snapshots on the treatment of Flavivirus infection

Progress continues at BioCryst in Q2

Quarterly developments discussed by PDL

Resten-NG continues progress in cardiovascular antisense program

Cubist awarded two SBIR grants

Structural GenomiX completes crystal structure of SARS coronavirus protease

New phase II trial studies of Genasense in combination with rituximab/fludarabine for CLL

Aventis and ImmunoGen combine forces to develop anticancer therapeutics

Antiemetic properties reported for known analgesic agent

Novel, more stable compositions of statin claimed

Selective A2B antagonists identified by OSI researchers

Schering-Plough patents new series of antiinflammatory compounds

Tachykinin antagonists with antiemetic activity described in recent patent

Inhibitors of beta-amyloid reported in the patent literature by BMS

Ropinirole slows progression of PD compared to levodopa therapy

Spirodiketopiperazine CCR5 antagonist enters the clinic as a potential new anti-HIV agent

Neovascular targeting therapy developed at Munich Biotech

Pleconaril safe and effective in the treatment of infections caused by picornaviruses

Evidence of visual memory improvement found with donepezil after TBI

Effective use of divalproex sodium described for cluster B personality disorder

Good activity profile established for dalbavancin against Gram-positive bacteria

Early detection of lymph node metastases in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...